Debt Free Direct
ADDFinancials from Lancashire-based debt advice and solutions counter Debt Free Direct (DFD) – originally backed by GCI at 44.5p – dazzled on every metric at the half year to the end of October.
Adjusted pre-tax profits powered ahead by almost 130% to £4.26m, sending earnings 146% higher to 7.66p, all on turnover up 91% to £12.2m. The interim dividend was doubled to 3p.
One minor blip was a move to new offices that caused disruption in Individual Voluntary Arrangement (IVA) volumes, although chief executive Andrew Redmond predicts strong volume growth for the second half.
DFD, which began paying dividends a year ago, has a robust balance sheet and says it is throwing off cash as a result of long-term growth in the number of IVA cases under supervision. Redmond said the IVA market is still a young and growing market place, and is sympathetic towards calls for regulation of the sector, with the group’s processes ‘regulation ready’. He also expressed excitement about growth in the UK, as well as for Debt Free Direct Australia, which began trading in August.
For the year to April, the City expects a rise in profits from £5.1m to £10.9m, and growth in earnings from 9.4p to 20.3p. For 2008, investors should set their stall out for 31p of earnings from profits of £16.7m. Those estimates place the 467p shares, which have taken a pause for breath after hitting a 52-week peak of 595p, on a lofty looking forward p/e ratio of 23 this year, falling to a more palatable 15 for April 2008.
We think the premium price is worth paying, with personal insolvencies burgeoning as borrowers overstretch themselves, and bumper growth looking assured. If you already own shares, consider topping up your holding. Add.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £174.7m
PE Forecast: 23
Share price: 467p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
